Vedolizumab proves to be superior to adalimumab for in achieving clinical remission and endoscopic improvement for ulcerative colitis, but not corticosteroid-free clinical remission.
Ustekinumab (Stelara, Janssen Biotech) was more effective at one year than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis, NEJM study shows.
Here’s a brief look at medications for rheumatologic disorders that were approved or granted a new indication in 2018.
Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.
Inflammatory bowel disease patients can be afflicted by various forms of arthritis from peripheral arthritis to ankylosing spondylitis and symmetrical polyarthritis. In this slideshow, we address identification, diagnosis and treatment for these complex cases.
Inflammatory bowel disease is associated with arthritis. Research suggests there could be a genetic component or the connection could be associated with an inflamed gut. Learn more here.
The gold standard for treating Crohn's disease and ulcerative colitis may lie in anti-TNF and anti-integrins therapy, researchers report this week.